Senate Democrats want to delay a vote on the nomination of President Trump's pick to lead the Department of Health and Human Services amid ethics concerns.

The Senate Finance Committee is slated to vote on the nomination of Rep. Tom Price (R-Ga.) Tuesday morning, but four Democrats are urging a pause because of "serious concerns" about "outstanding and significant questions about [Price's] qualifications and ethical conduct."

Democratic Sens. Patty Murray Patricia (Patty) Lynn MurrayTrump health officials grilled over reports of politics in COVID-19 response CDC director pushes back on Caputo claim of 'resistance unit' at agency The Hill's Morning Report - Sponsored by The Air Line Pilots Association - Pence lauds Harris as 'experienced debater'; Trump, Biden diverge over debate prep MORE, Al Franken Alan (Al) Stuart FrankenGOP Senate candidate says Trump, Republicans will surprise in Minnesota Peterson faces fight of his career in deep-red Minnesota district Getting tight — the psychology of cancel culture MORE, Tammy Baldwin Tammy Suzanne BaldwinKeep teachers in the classroom Cher raised million for Biden campaign at LGBTQ-themed fundraiser Democrats seek balance in backing protests, condemning violence MORE and Elizabeth Warren Elizabeth WarrenBiden's fiscal program: What is the likely market impact? Warren, Schumer introduce plan for next president to cancel ,000 in student debt The Hill's 12:30 Report - Presented by Facebook - Don't expect a government check anytime soon MORE asked in a letter to Senate leadership that the vote be postponed until Price answers questions about his financial investments.

All four sit on the Senate's Health, Education, Labor and Pensions Committee (HELP), which questioned Price earlier this month.

ADVERTISEMENT

Price should also "and has provided documents sought in connection with his inappropriate and potentially illegal investment activities," the letter said.

It's unlikely that Republicans will move to delay the vote. Hatch last week dismissed questions about Price's stock holdings as "grossly exaggerated" and "distorted."

The letter follows another report out Monday detailing Price's alleged conflicts of interests.

The Wall Street Journal reported that Price was part of an exclusive group that was able to buy stock in a biotech company at a discount.